Lupin share price
You have to be logged in to add this to Watchlist.- ₹1,970.85(0.76%)November 7, 2025 15:29:57 PM IST
- NSE
- BSE
- Vol : 3.71M (NSE + BSE)Last 20 day avg : 1.02 M
Lupin is trading 0.76% upper at Rs 1,970.85 as compared to its last closing price. Lupin has been trading in the price range of 2,001.75 & 1,960.85. Lupin has given -16.99% in this year & -0.02% in the last 5 days. Lupin has TTM P/E ratio 23.90 as compared to the sector P/E of 23.79.There are 34 analysts who have initiated coverage on Lupin. There are 9 analysts who have given it a strong buy rating & 12 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 1,477.92 Crores in its last quarter.Listed peers of Lupin include Dr Reddys Laboratories (0.02%), Zydus Lifesciences (0.81%), Lupin (0.76%).The Mutual Fund holding in Lupin was at 20.57% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Lupin was at 20.50% in 30 Sep 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Nov 09, 2025, 01:00 AM UTC
- BetaLow volatility0.71Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.32The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.61Annual dividends as a percentage of the stock price.
- P/BIn line with historical values5.19The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values24.21Price-to-earnings ratio based on trailing 12-month earnings
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in September quarter by 24.23% from Rs 7047.51 crore to Rs 5672.73 crore, year-on-year
- The company has grown its September quarter profit by 73.35% from Rs 852.58 crore to Rs 1477.92 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,018.63
- R2
- 2,051.42
- R3
- 2,087.83
- S1
- 1,949.43
- S2
- 1,913.02
- S3
- 1,880.23
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Dr Reddys Laboratories | Bearish | 1,205.30 | 0.02 | 1,00,591.29 | 19.00 | 3.2 | 0.62 | 2.34 |
| Zydus Lifesciences | Bearish | 943.80 | 0.81 | 94,968.37 | 21.43 | 4.2 | 1.10 | 0.13 |
| Lupin | Moderately Bullish | 1,970.85 | 0.76 | 90,020.98 | 27.27 | 5.19 | 0.41 | 11.80 |
| Abbott India | Bearish | 28,825.00 | -2.22 | 61,251.12 | 53.21 | 17.78 | 1.34 | 3.73 |
| Alkem Laboratories | Bullish | 5,674.30 | 0.54 | 68,008.65 | 26.62 | 4.81 | 0.93 | 4.83 |
- Promoter(s) holding is moderate at 46.90%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.75 percentage points from previous quarter
- Mutual Funds holding has increased by 1.22 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-06 | Quarterly Results & Others |
| 2025-08-05 | Quarterly Results & Others |
| 2025-05-14 | Audited Results & Final Dividend |
| 2025-02-11 | Quarterly Results & Others |
| 2024-11-07 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE326A01037
- BSE Code500257
- NSE CodeLUPIN
Lupin is trading at 1970.85 as on Fri Nov 07 2025 09:59:57. This is 0.76% upper as compared to its previous closing price of 1956.05.
The market capitalization of Lupin is 90020.98 Cr as on Fri Nov 07 2025 09:59:57.
The average broker rating on Lupin is Buy. The breakup of analyst rating is given below -
- 9 analysts have given a strong buy rating
- 12 analysts have given a buy rating
- 11 analysts have given a hold rating
- 2 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Lupin is 2403.45 whereas the 52 wk low is 1774.00
Lupin can be analyzed on the following key metrics -
- TTM P/E: 23.90
- Sector P/E: 23.79
- Dividend Yield: 0.61%
- D/E ratio: -
Lupin reported a net profit of 3281.62 Cr in 2025.
The Mutual Fund Shareholding was 20.57% at the end of 30 Sep 2025.